Vanda Pharmaceuticals Inc.

ALURIN

Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of a craving; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of a behavioral stressor; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases;

APRILIOS

Pharmaceutical and medicinal preparations for the treatment of gastroparesis, pruritus, atopic dermatitis, and motion sickness; pharmaceutical products for the treatment of gastroparesis, pruritus, atopic dermatitis, and motion sickness;The English translation of APRILIOS in the mark is April.;

APRILIOS

Pharmaceutical and medicinal preparations; pharmaceutical products;

AURALIS

Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of a craving; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of a behavioral stressor; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases;

CORICO

Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of a craving; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of a behavioral stressor; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases;

ELORIUM

Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of a craving; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of a behavioral stressor; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases;

ENTRAYNIA

Pharmaceutical preparations for use in the treatment of diseases and disorders of the central nervous system, namely, diseases and disorders related to circadian rhythm; diseases and disorders having an impact on the central nervous system,, namely, diseases and disorders having an impact on circadian rhythm; and diseases and disorders having a central nervous system manifestation,, namely, diseases and disorders manifesting in symptoms related to circadian rhythm;

ENTRAYNIA

Pharmaceutical preparations for use in the treatment of diseases and disorders of the central nervous system, namely, diseases and disorders related to circadian rhythm; Pharmaceutical preparations for use in the treatment of diseases and disorders having an impact on the central nervous system, namely, diseases and disorders having an impact on circadian rhythm; and Pharmaceutical preparations for use in the treatment of diseases and disorders having a central nervous system manifestation, namely, diseases and disorders manifesting in symptoms related to circadian rhythm;

ENTRAYNIA

Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of circadian rhythm diseases and disorders; Pharmaceutical preparations for the treatment of Non-24-Hour Sleep-Wake Disorder; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the reduction of cravings for alcohol, food, nicotine, opioids, or opiates; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of motion sickness; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for the treatment of fatigue; Pharmaceutical preparations for the treatment of narcolepsy; Pharmaceutical preparations for the treatment of levodopa-induced dyskinesias in Parkinson's Disease; Pharmaceutical preparations for the treatment of viral pneumonia; Pharmaceutical preparations for the treatment of social anxiety disorder and social anxiety disorder performance-only subtype; Pharmaceutical preparations for the treatment of respiratory distress, acute respiratory distress syndrome, and inflammatory lung injury; Pharmaceutical preparations for the treatment of gastric motility and gastric emptying disorders; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of multiple myeloma; Pharmaceutical preparations for facilitating emergence from general anesthesia; Pharmaceutical preparations for improving cognition; Pharmaceutical preparations, namely, antivirals;

EVEXIAZ

Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of a craving; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of a behavioral stressor; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases;

F FANAPT ILOPERIDONE

The mark consists of stylized text reading Fanapt above stylized text reading iloperidone; each below an approximately vertically rectangular shape with rounded corners which is bisected substantially horizontally by a stylized lower case letter f.;Pharmaceutical preparations and substances for use in the treatment of the central nervous system;Color is not claimed as a feature of the mark.;ILOPERIDONE;